Expertise in
8
conditions

Kenji Okami

Isehara, JP 
Expertise in
8
conditions
Isehara, JP 

Overview

Kenji Okami practices practicing medicine in Isehara, Japan.

Mr. Okami is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Salivary Gland Tumors, Laryngeal Cancer, Throat Cancer, Tissue Biopsy, and Endoscopy.

He is actively involved in clinical research, co-authoring 122 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Isehara, Japan
Other Locations
Head And Neck Surgery, Kanagawa, Japan
Otorhinolaryngology/Head And Neck Surgery, Tokai, 2591193, Japan
Department Of Otolaryngology Head And Neck Surgery, Sapporo, Japan
Hiratsuka, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3

122 Total Publications

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 26, 2026

Frequently Asked Questions about Kenji Okami

Is Kenji Okami a top-rated expert for Salivary Gland Tumors?

MediFind is an objective health platform that identifies experts based on real-world data. Kenji Okami is classified as an Distinguished expert for Salivary Gland Tumors, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kenji Okami participate in research or clinical trials?

Yes. Kenji Okami has published 122 articles and abstracts on conditions like Salivary Gland Tumors. You can view a list of Kenji Okami's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Okami's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile